Updated American Urological Association (AUA) guidelines for treating benign prostatic hyperplasia (BPH) include recommendations that laboratory testing include a PSA test and a urinalysis to rule out infection or other causes of lower urinary tract symptoms (LUTS).
The revised guidelines, which update the original BPH guidelines released in 2003, are expected to be published in an upcoming issue of The Journal of Urology, include a detailed diagnostic algorithm to guide a physician in diagnosing and treating LUTS secondary to BPH, as well as detailed information on basic management and the management of complicated cases.
In the guidelines, the AUA recommends that physicians treating men with suspected cases of LUTS should obtain a relevant medical history, use the AUA Symptom Index to assess symptoms, and conduct a full physical examination.
Additional updates to the 2003 version of the guidelines also include:
- Added recommendations for the use of anti-cholinergic drugs and the use of laser therapies
- Lowered index patient age from 50 to 45, to better guide physicians in treating younger men who may be experiencing lower urinary symptoms
- Cautionary statements regarding intraoperative floppy iris syndrome in cataract patients taking alpha-blockers to treat BPH
“The increasing life expectancy and growth of our elderly population will increase the number of men who suffer from LUTS. This will place increased demands for treatment services, and necessitate the incorporation of evidence-based medicine in that treatment,” said Kevin T. McVary, MD, chair of the panel that developed the guidelines. “This document provides much-needed guidance to doctors who are already treating LUTS, as well as those who will be in the future.”
For more information about the updated guidelines, visit the AUA site.